Sirgo joins the company with more than 35 years of pharmaceutical industry experience and is most recognized for building the fully integrated pharmaceutical company, BioDelivery Sciences International (NASDAQ: BDSI).
With the appointment of Dr. Sirgo to the senior leadership team, Dr. Steven Stice, co-founder, current CEO and chief scientific officer, will fully focus on directing the company's research and scientific development efforts.
ArunA continues the development of its novel neural exosome platform to optimise the delivery of siRNAs, antibodies, genes and small molecules across the blood brain barrier to improve outcomes for patients with CNS and neurodegenerative disorders including genetic and rare diseases.
Dr. Sirgo most recently served as president and chief executive officer of BioDelivery Sciences, a publicly listed fully integrated specialty pharmaceutical company with a focus in pain/CNS drug development and commercialization.
In this role, he successfully raised over USD600 m through equity, debt and partnerships and utilized the company's drug delivery platform to progress three products through FDA approval and commercialization.
Prior to joining BioDelivery Services, he spent 16 years in a range of clinical and commercial leadership positions at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including vice president of International OTC Development and vice president of New Product Marketing.
Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate in Pharmacy from Philadelphia College of Pharmacy and Science.
ArunA Bio is revolutionizing neurotherapeutic development with our neural exosome therapeutic platform. The inherent ability of our proprietary neural exosomes to cross the blood brain barrier enables drugs and drug combinations to naturally target cells and treat patients with a range of neurological disorders.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval